Kiniksa Pharmaceuticals (KNSA) News Today $26.70 -0.04 (-0.15%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$26.12 -0.58 (-2.17%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Balyasny Asset Management L.P. Purchases New Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Balyasny Asset Management L.P. purchased a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,921 shares of the compMay 20 at 3:55 AM | marketbeat.comBNP Paribas Financial Markets Has $3.43 Million Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)BNP Paribas Financial Markets lowered its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 173,480 sharesMay 17, 2025 | marketbeat.comSanj K. Patel Sells 2,872 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockMay 16, 2025 | insidertrades.comParkman Healthcare Partners LLC Boosts Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Parkman Healthcare Partners LLC grew its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 765,453 shares of the company's stock after buying an additiMay 16, 2025 | marketbeat.comJefferies Financial Group Inc. Has $2.22 Million Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Jefferies Financial Group Inc. increased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 39.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 24,463 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 32.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 99,6May 15, 2025 | marketbeat.comHudson Bay Capital Management LP Has $4.45 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Hudson Bay Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 150.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 225,000 shares of the company's stock after buying aMay 15, 2025 | marketbeat.comJane Street Group LLC Has $3.75 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Jane Street Group LLC decreased its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 45.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 189,452 shares of the company'sMay 15, 2025 | marketbeat.comLion Point Capital LP Has $908,000 Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Lion Point Capital LP trimmed its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 25.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 45,900 shares of the company's stock after selling 15,500 shares during the period. KiniMay 14, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 60,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Schonfeld Strategic Advisors LLC reduced its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 68.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,400 shares of the comMay 13, 2025 | marketbeat.comGranahan Investment Management LLC Sells 44,259 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Granahan Investment Management LLC trimmed its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 463,110 shares ofMay 12, 2025 | marketbeat.comDriehaus Capital Management LLC Reduces Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Driehaus Capital Management LLC lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 16.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 613,55May 12, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 29,300 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Dimensional Fund Advisors LP increased its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 3.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 771,607 shares of the company's stock after buying an additional 29,300 shMay 11, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock Holdings Lessened by Fairmount Funds Management LLCFairmount Funds Management LLC cut its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 31.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,194,341 shares of the company's stock after selling 1,010,500 shares during the period. KiMay 10, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells $470,998.43 in StockMay 10, 2025 | insidertrades.comAlgert Global LLC Purchases 44,655 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Algert Global LLC grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 49.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135,814 shares of the company's stock aftMay 10, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Bought by Braidwell LPBraidwell LP increased its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 19.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,452,447 shares of the company's stock after acquiring an additioMay 8, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 1-Year High - What's Next?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 12-Month High - Still a Buy?May 7, 2025 | marketbeat.comArrowMark Colorado Holdings LLC Has $10.32 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)ArrowMark Colorado Holdings LLC trimmed its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 1.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 521,889 shares of the company's stock after selling 9,397 sharesMay 6, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider Ross Moat Sells 6,272 SharesMay 6, 2025 | insidertrades.comInvesco Ltd. Sells 41,380 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Invesco Ltd. trimmed its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 74.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,108 shares of the company's stock after sellinMay 6, 2025 | marketbeat.comKiniksa Pharmaceuticals: Making Steady ProgressMay 5, 2025 | seekingalpha.comResearch Analysts Set Expectations for KNSA Q2 EarningsKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Stock analysts at Wedbush decreased their Q2 2025 EPS estimates for shares of Kiniksa Pharmaceuticals in a report released on Tuesday, April 29th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.24 per shareMay 4, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Rating of "Buy" by AnalystsShares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) have earned a consensus rating of "Buy" from the six analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target prMay 4, 2025 | marketbeat.comWhat is Wedbush's Estimate for KNSA Q1 Earnings?Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Research analysts at Wedbush issued their Q1 2026 EPS estimates for shares of Kiniksa Pharmaceuticals in a note issued to investors on Tuesday, April 29th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings oMay 3, 2025 | marketbeat.comPDT Partners LLC Increases Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)PDT Partners LLC boosted its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 74.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 64,917 shares of the company's stock after buying an additional 27,675 sharMay 3, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comMark Ragosa Sells 21,254 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockMay 2, 2025 | insidertrades.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Gap Up Following Earnings BeatKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Gap Up Following Strong EarningsMay 1, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Announces Quarterly Earnings ResultsKiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.06 by $0.05. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%.May 1, 2025 | marketbeat.comKiniksa Pharmaceuticals Reports Strong Q1 2025 Financial Results with 75% Growth in ARCALYST Revenue and Increased 2025 GuidanceApril 30, 2025 | nasdaq.comKNSA Crosses Above Key Moving Average LevelApril 30, 2025 | nasdaq.comKiniksa Pharmaceuticals International PLC (KNSA) Q1 2025 Earnings Report Preview: What To Look ForApril 30, 2025 | finance.yahoo.comKiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent PericarditisApril 30, 2025 | globenewswire.comKiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio ExecutionApril 29, 2025 | msn.comKiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everything You Need To Know Ahead Of ...April 29, 2025 | finance.yahoo.comKiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio ExecutionApril 29, 2025 | globenewswire.comJump Financial LLC Sells 31,006 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Jump Financial LLC trimmed its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 68.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,601 shares of the company's stApril 29, 2025 | marketbeat.com199,953 Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Purchased by Raymond James Financial Inc.Raymond James Financial Inc. bought a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 199,953 shares of the company's stock, valued at approximately $3,955,0April 29, 2025 | marketbeat.comOberweis Asset Management Inc. Increases Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Oberweis Asset Management Inc. grew its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 18.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,200 shares of the cApril 27, 2025 | marketbeat.comKiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025April 24, 2025 | globenewswire.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider Ross Moat Sells 18,259 SharesApril 24, 2025 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells 12,000 Shares of StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 12,000 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $20.48, for a total transaction of $245,760.00. Following the transaction, the chief operating officer now directly owns 77,363 shares of the company's stock, valued at $1,584,394.24. This represents a 13.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.April 18, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Outperform Rating from WedbushWedbush restated an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Wednesday.April 18, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 12,000 SharesApril 17, 2025 | insidertrades.comEvercore ISI Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)April 16, 2025 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)April 16, 2025 | markets.businessinsider.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Up 6.3% - Still a Buy?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Up 6.3% - What's Next?April 16, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 277,827 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)JPMorgan Chase & Co. boosted its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 138.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 477,800 shares of the company's stock after purchasingApril 16, 2025 | marketbeat.comKiniksa Pharmaceuticals (KNSA) Expected to Announce Earnings on TuesdayKiniksa Pharmaceuticals (NASDAQ:KNSA) will be releasing earnings before the market opens on Tuesday, April 22, Financial Modeling Prep reports.April 16, 2025 | marketbeat.com Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address KNSA Media Mentions By Week KNSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼1.360.65▲Average Medical News Sentiment KNSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼104▲KNSA Articles Average Week Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Revolution Medicines News Elanco Animal Health News Blueprint Medicines News BridgeBio Pharma News Verona Pharma News Telix Pharmaceuticals Limited American Depositary Shares News TG Therapeutics News Grifols News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
